Nanobody: outstanding features for diagnostic and therapeutic applications
- 31 Downloads
Nanobodies (Nbs) have arisen as an alternative to conventional antibodies (Abs) and show great potential when used as tools in different biotechnology fields such as diagnostics and therapy. Different approaches have been described for the production of Nbs and these methods face new challenges focused on improving yield, affinity, and reducing production costs. This review summarizes these challenges, and also the latest advances in the detection of different kinds of molecules, such as proteins and small molecules, and describes their potential use for noninvasive in vivo imaging and for in vitro assays. Moreover, the unique properties of Nbs are outlined like internalization, size, thermal and chemical stability, affinity, blood clearance, and labeling procedures. Concerning therapeutic applications, we highlight some already reported examples about Nbs being used for the treatment of several diseases such as cancer, neurodegenerative or infectious diseases among others. Finally, future trends, opportunities, and disadvantages are also discussed.
KeywordsNanobody Imaging Therapeutic Diagnosis Immunoassays Single-domain antibody
This work has been funded by the ImmunoQS project funded by MINECO, Programa Estatal de Investigación Desarrollo e Innovación Orientada a los Retos de la Sociedad (SAF2015-67476-R). The Nb4D group is a consolidated research group (Grup de Recerca) of the Generalitat de Catalunya and has support from the Departament d’Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (expedient: 2017 SGR 1441). CIBER-BBN is an initiative funded by the Spanish National Plan for Scientific and Technical Research and Innovation 2013-2016, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions are financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82(1):775–97. https://doi.org/10.1146/annurev-biochem-063011-092449.Google Scholar
- 3.Ingram JR, Schmidt FI, Ploegh HL. Exploiting nanobodies’ singular traits. In: Littman DR, Yokoyama WM, editors. Annual review of immunology, vol 36. Annu rev Immunol. 2018; 695–715. https://doi.org/10.1146/annurev-immunol-042617-053327.
- 5.Muyldermans S, Baral TN, Retamozzo VC, De Baetselier P, De Genst E, Kinne J, Leonhardt H, Magez S, Nguyen VK, Revets H, Rothbauer U, Stijlemans B, Tillib S, Wernery U, Wyns L, Hassanzadeh-Ghassabeh G, Saerens D. Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol. 2009;128:178–183. https://doi.org/10.1016/j.vetimm.2008.10.299.
- 13.Iezzi ME, Policastro L, Werbajh S, Podhajcer O, Canziani GA. Single-domain antibodies and the promise of modular targeting in cancer imaging and treatment. Front Immunol. 2018;9:273. https://doi.org/10.3389/fimmu.2018.00273.
- 19.Robert B, Dorvillius M, Buchegger F, Garambois V, Mani JC, Pugnieres M, et al. Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA). Int J Cancer. 1999;81(2):285–91.Google Scholar
- 22.Davies J, Riechmann L. Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability. Protein Eng. 1996;9(6):531–7.Google Scholar
- 23.Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 1997;414(3):521–6.Google Scholar
- 24.Perez JM, Renisio JG, Prompers JJ, van Platerink CJ, Cambillau C, Darbon H, et al. Thermal unfolding of a llama antibody fragment: a two-state reversible process. Biochemistry. 2001;40(1):74–83.Google Scholar
- 27.Wang J, Mukhtar H, Ma L, Pang Q, Wang X. VHH antibodies: reagents for mycotoxin detection in food products. Sensors. 2018;18(2):485.Google Scholar
- 30.Padlan EA. X-ray crystallography of antibodies. Adv Protein Chem. 1996;49:57–133.Google Scholar
- 31.Conrath KE, Lauwereys M, Galleni M, Matagne A, Frere JM, Kinne J, Wyns L, Muyldermans S. Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the Camelidae. Antimicrob Agents Chemother. 2001;45(10):2807–2812. https://doi.org/10.1128/aac.45.10.2807-2812.2001.
- 39.Campuzano S, Salema V, Moreno-Guzmán M, Gamella M, Yáñez-Sedeño P, Fernández LA, et al. Disposable amperometric magnetoimmunosensors using nanobodies as biorecognition element. Determination of fibrinogen in plasma. Biosens Bioelectron. 2014;52:255–60. https://doi.org/10.1016/j.bios.2013.08.055.Google Scholar
- 50.Tang X, Li P, Zhang Q, Zhang Z, Zhang W, Jiang J. Time-resolved fluorescence immunochromatographic assay developed using two idiotypic nanobodies for rapid, quantitative, and simultaneous detection of aflatoxin and zearalenone in maize and its products. Anal Chem. 2017;89(21):11520–8. https://doi.org/10.1021/acs.analchem.7b02794.Google Scholar
- 51.Traenkle B, Rothbauer U. Under the microscope: single-domain antibodies for live-cell imaging and super-resolution microscopy. Front Immunol. 2017;8:1030. https://doi.org/10.3389/fimmu.2017.01030.
- 54.Gainkam LOT, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I, et al. Comparison of the biodistribution and tumor targeting of two Tc-99m-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008;49(5):788–95. https://doi.org/10.2967/jnumed.107.048538.Google Scholar
- 55.Debie P, Van Quathem J, Hansen I, Bala G, Massa S, Devoogdt N, et al. Effect of dye and conjugation chemistry on the biodistribution profile of near-infrared-labeled nanobodies as tracers for image-guided surgery. Mol Pharm. 2017;14(4):1145–53. https://doi.org/10.1021/acs.molpharmaceut.6b01053.Google Scholar
- 56.Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–7.Google Scholar
- 57.Fraser G, Smith CA, Imrie K, Meyer R, Hematology Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. Alemtuzumab in chronic lymphocytic leukemia. Curr Oncol. 2007;14(3):96–109.Google Scholar
- 62.Lafaye P, Achour I, England P, Duyckaerts C, Rougeon F. Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. Mol Immunol. 2009;46(4):695–704. https://doi.org/10.1016/j.molimm.2008.09.008.Google Scholar